Literature DB >> 20494703

Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma.

Kelvin Hong1, Jean-Francois H Geschwind.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a rare hepatic malignancy that for patients with unresectable disease is uniformly fatal. Only approximately 30% of patients are eligible for resection because of the advanced nature of the disease at the time of diagnosis. Systemic chemotherapy has been disappointing in regard to its efficacy, with most regimens resulting in a median survival of 6 to12 months. There has been great interest in other modalities of treatment, particularly intra-arterial therapies, which consist of a catheter-based group of treatments where therapeutic and/or embolic agents are intra-arterially injected to target the liver tumors. In this report, we attempt to employ an evidence-based approach to critically review and comprehend the current role and future potential of intra-arterial therapies for ICC. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494703     DOI: 10.1053/j.seminoncol.2010.03.002

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  15 in total

Review 1.  Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects.

Authors:  Lynn Jeanette Savic; Julius Chapiro; Jean-François H Geschwind
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

Review 2.  Cholangiocarcinoma--controversies and challenges.

Authors:  Tushar Patel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04       Impact factor: 46.802

Review 3.  Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review.

Authors:  Linda Yang; Jocelyn Shan; Leonard Shan; Akshat Saxena; Lourens Bester; David L Morris
Journal:  J Gastrointest Oncol       Date:  2015-10

4.  Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis.

Authors:  Cristina Mosconi; Leonardo Solaini; Giulio Vara; Nicolò Brandi; Alberta Cappelli; Francesco Modestino; Alessandro Cucchetti; Rita Golfieri
Journal:  Cardiovasc Intervent Radiol       Date:  2021-03-11       Impact factor: 2.740

5.  Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists.

Authors:  Shanmugasundaram Ganapathy-Kanniappan; Rani Kunjithapatham; Michael S Torbenson; Pramod P Rao; Kathryn A Carson; Manon Buijs; Mustafa Vali; Jean-François H Geschwind
Journal:  Radiology       Date:  2012-03       Impact factor: 11.105

6.  Recurrence after operative management of intrahepatic cholangiocarcinoma.

Authors:  Omar Hyder; Ioannis Hatzaras; Georgios C Sotiropoulos; Andreas Paul; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Bryan M Clary; Luca Aldrighetti; Cristina R Ferrone; Andrew X Zhu; Todd W Bauer; Dustin M Walters; Ryan Groeschl; T Clark Gamblin; J Wallis Marsh; Kevin T Nguyen; Ryan Turley; Irinel Popescu; Catherine Hubert; Stephanie Meyer; Michael A Choti; Jean-Francois Gigot; Gilles Mentha; Timothy M Pawlik
Journal:  Surgery       Date:  2013-03-15       Impact factor: 3.982

7.  Hepatic arterial infusion with oxaliplatin and 5-FU/folinic acid for advanced biliary tract cancer: a phase II study.

Authors:  M Sinn; A Nicolaou; B Gebauer; P Podrabsky; D Seehofer; J Ricke; B Dörken; H Riess; B Hildebrandt
Journal:  Dig Dis Sci       Date:  2013-03-24       Impact factor: 3.199

8.  Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis.

Authors:  Samdeep Mouli; Khairuddin Memon; Talia Baker; Al B Benson; Mary F Mulcahy; Ramona Gupta; Robert K Ryu; Riad Salem; Robert J Lewandowski
Journal:  J Vasc Interv Radiol       Date:  2013-04-19       Impact factor: 3.464

Review 9.  Decision Making: Intra-arterial Therapies for Cholangiocarcinoma-TACE and TARE.

Authors:  Brian M Currie; Michael C Soulen
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

Review 10.  Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma.

Authors:  Shanmugasundaram Ganapathy-Kanniappan; Rani Kunjithapatham; Jean-Francois Geschwind
Journal:  Oncotarget       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.